The value of p16 and HPV DNA in non-tonsillar, non-base of tongue oropharyngeal cancer

References

• Nasman A, Bersani C, Lindquist D, et al. Human papillomavirus and potentially relevant biomarkers in tonsillar and base of tongue squamous cell carcinoma. Anticancer Res. 2017;37(10):5319–5328.
   PubMed Web of Science ®Google Scholar
• Haeggblom L, Ramqvist T, Tommasino M, et al. Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years. Papillomavirus Res. 2017;4:1–11.
   PubMed Web of Science ®Google Scholar
• Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007;110(7):1429–1435.
   PubMed Web of Science ®Google Scholar
• Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009;125(2):362–366.
   PubMed Web of Science ®Google Scholar
• Attner P, Du J, Nã¤Sman A, et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer. 2010;126(12):NA–84.
   Web of Science ®Google Scholar
• Attner P, Du J, Nasman A, et al. Human papillomavirus and survival in patients with base of tongue cancer. Int J Cancer. 2011;128(12):2892–2897.
   PubMed Web of Science ®Google Scholar
• Mellin H, Friesland S, Lewensohn R, et al. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer. 2000;89(3):300–304.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709–720.
   PubMed Web of Science ®Google Scholar
• Amin MB, Edge SB, Gress DM, et al., editors. American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. 8th ed. Chicago, IL: American Joint Committee on Cancer, Springer; 2017.
   Google Scholar
• Ljokjel B, Lybak S, Haave H, et al. The impact of HPV infection on survival in a geographically defined cohort of oropharynx squamous cell carcinoma (OPSCC) patients in whom surgical treatment has been one main treatment. Acta Otolaryngol. 2014;134(6):636–645.
   PubMed Web of Science ®Google Scholar
• Marklund L, Nasman A, Ramqvist T, et al. Prevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer. Cancer Med. 2012;1(1):82–88.
   PubMed Web of Science ®Google Scholar
• Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007;121(11):2465–2472.
   PubMed Web of Science ®Google Scholar
• Gelwan E, Malm IJ, Khararjian A, et al. Nonuniform distribution of high-risk human papillomavirus in squamous cell carcinomas of the oropharynx: rethinking the anatomic boundaries of oral and oropharyngeal carcinoma from an oncologic HPV perspective. Am J Surg Pathol. 2017;41(12):1722–1728.
   PubMed Web of Science ®Google Scholar
• Tham T, Ahn S, Frank D, et al. Anatomical subsite modifies survival in oropharyngeal squamous cell carcinoma: National Cancer Database study. Head Neck. 2020;42(3):434–445.
   PubMed Web of Science ®Google Scholar
• Dalianis T, Grun N, Koch J, et al. Human papillomavirus DNA and p16(INK4a) expression in hypopharyngeal cancer and in relation to clinical outcome, in Stockholm, Sweden. Oral Oncol. 2015;51(9):857–861.
   PubMed Web of Science ®Google Scholar
• Nasman A, Andersson E, Marklund L, et al. HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome. PLoS One. 2013;8(10):e77025.
   PubMed Web of Science ®Google Scholar
• Fakhry C, Zhang Q, Gillison ML, et al. Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials. Cancer. 2019;125(12):2027–2038.
   PubMed Web of Science ®Google Scholar
• Jones DA, Mistry P, Dalby M, et al. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. Eur J Cancer. 2020;124:178–185.
   PubMed Web of Science ®Google Scholar
• Craig SG, Anderson LA, Schache AG, et al. Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach. Br J Cancer. 2019;120(8):827–833.
   PubMed Web of Science ®Google Scholar